We provide consulting services in drug discovery. As computational modellers, we work at the interface between chemistry, biochemistry, and structural biology.

Our focus is the discovery and design of bioactive molecules.

We specialize in working with early-phase small-molecule biotech companies, to help

• translate academic IP into a commercial entity
• jump-start the drug discovery efforts, e.g. by finding novel chemical starting points
• turn Xray structures into ideas for ligands
• overcome obstacles, especially in situations where the data just don't make sense.

John H Van Drie , the principal of Van Drie Research, has over 20 years experience in drug discovery, having worked at Pharmacia, Vertex, Novartis, and having consulted to a variety of drug discovery organizations. As a scientist, he has contributed to the discovery of three marketed drugs:

• Abbott's ritonavir, the first marketed HIV protease inhibitor for AIDS infections,
• Upjohn's linezolid, for resistant gram-positive bacterial infections (now Pfizer's),
• Vertex's telaprevir, the leading drug for hepatitis C infections

Click here for his publications, and more on his background.

Furthermore, we firmly believe that excellent teamwork is essential to successful drug discovery. To that end, we also assist clients with team-building and teamwork. Van Drie Research has teamed up with Breck Arnzen and Bob Putnam to bring a variety of ‘social technologies’ to bear on our clients’ challenges.